• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis.

作者信息

Miller Peter, Elias Pierre, Einstein Andrew J, Maurer Mathew S, Ahmed Gasmelseed Y, Poterucha Timothy J

机构信息

Department of Medicine (P.M., P.E., A.J.E., M.S.M., T.J.P.), Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York.

Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine (P.E., A.J.E., M.S.M., G.Y.A., T.J.P.), Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York.

出版信息

Circ Heart Fail. 2024 Dec;17(12):e012075. doi: 10.1161/CIRCHEARTFAILURE.124.012075. Epub 2024 Nov 7.

DOI:10.1161/CIRCHEARTFAILURE.124.012075
PMID:39508097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11652229/
Abstract
摘要

相似文献

1
Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis.社会经济差异与转甲状腺素蛋白心脏淀粉样变患者延迟使用塔法米迪斯有关。
Circ Heart Fail. 2024 Dec;17(12):e012075. doi: 10.1161/CIRCHEARTFAILURE.124.012075. Epub 2024 Nov 7.
2
Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis.在转甲状腺素蛋白心脏淀粉样变患者中，塔非酰胺治疗期间心肌肌钙蛋白水平升高的预后影响
J Clin Med. 2023 Jul 12;12(14):4631. doi: 10.3390/jcm12144631.
3
From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics.从转甲状腺素蛋白心脏淀粉样变的诊断到氯苯唑酸治疗：停药与患者社会人口学特征的关联
Am J Health Syst Pharm. 2024 Dec 5;81(24):1245-1251. doi: 10.1093/ajhp/zxae183.
4
A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.关于转甲状腺素蛋白心脏淀粉样变患者塔法米迪司给药的声明。
Circ J. 2019 Dec 25;84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16.
5
[Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].[心脏转甲状腺素蛋白淀粉样变性的诊断与治疗。使用氯苯唑酸的创新疗法。]
Rev Med Liege. 2022 Jan;77(1):63-68.
6
Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France.2788例转甲状腺素蛋白淀粉样变性患者的临床结局：法国曲氟胺葡甲胺早期获取项目
Arch Cardiovasc Dis. 2025 Feb;118(2):123-132. doi: 10.1016/j.acvd.2024.08.006. Epub 2024 Oct 5.
7
Experience with tafamidis in peritoneal dialysis for a patient diagnosed with transthyretin cardiac amyloidosis.他法米地用于一名被诊断为转甲状腺素蛋白心脏淀粉样变患者的腹膜透析的经验。
Clin Kidney J. 2024 Jul 29;17(8):sfae233. doi: 10.1093/ckj/sfae233. eCollection 2024 Aug.
8
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.对比塔法米迪与肝移植作为遗传性转甲状腺素蛋白淀粉样变性的一线治疗方法。
Amyloid. 2023 Sep;30(3):303-312. doi: 10.1080/13506129.2023.2177986. Epub 2023 Feb 16.
9
Follow-up Tc-99 m pyrophosphate cardiac scan for patients with transthyretin cardiac amyloidosis treated with tafamidis.用特立氟胺治疗转甲状腺素蛋白心脏淀粉样变患者后的 Tc-99m 焦磷酸盐心脏扫描随访。
Jpn J Radiol. 2023 Aug;41(8):882-888. doi: 10.1007/s11604-023-01403-4. Epub 2023 Mar 15.
10
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).在使用他法米地治疗的转甲状腺素蛋白淀粉样心肌病真实世界患者队列中的生存情况：来自转甲状腺素蛋白淀粉样变性病结局调查（THAOS）的分析
J Card Fail. 2025 Mar;31(3):525-533. doi: 10.1016/j.cardfail.2024.06.003. Epub 2024 Jun 21.

本文引用的文献

1
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).世界心脏联合会关于转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的共识。
Glob Heart. 2023 Oct 26;18(1):59. doi: 10.5334/gh.1262. eCollection 2023.
2
Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer.指导 amyloidosis 治疗药物处方的复杂网络：入门。
J Am Heart Assoc. 2022 Apr 5;11(7):e023895. doi: 10.1161/JAHA.121.023895. Epub 2022 Mar 18.
3
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.野生型转甲状腺素蛋白心脏淀粉样变患者的早期诊断和转归。
Mayo Clin Proc. 2021 Aug;96(8):2185-2191. doi: 10.1016/j.mayocp.2021.04.021.
4
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
5
Transthyretin (TTR) cardiac amyloidosis.转甲状腺素蛋白（TTR）心脏淀粉样变性
Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915.